Holen Sie sich die Stockscreener-App
4.89
1.26%
-0.05
Schlusskurs vom Vortag:
$4.94
Offen:
$5
24-Stunden-Volumen:
3.04M
Relative Volume:
0.11
Marktkapitalisierung:
$2.09B
Einnahmen:
$64.60M
Nettoeinkommen (Verlust:
$-377.75M
KGV:
-3.1548
EPS:
-1.55
Netto-Cashflow:
$-335.64M
1W Leistung:
-11.63%
1M Leistung:
-24.84%
6M Leistung:
-40.07%
1J Leistung:
-37.54%
1-Tages-Spanne:
$4.84
$5.03
1-Wochen-Bereich:
$4.72
$5.54
52-Wochen-Spanne:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Vergleichen Sie RXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.8997 | 2.40B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.65 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.00 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
457.82 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
699.83 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.52 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals Inc.’s Beta Climbs After Market VolatilityMarket Performance Report & Free Weekly Chart Analysis and Trade Guides - classian.co.kr
Why is RXRX Stock Declining? - StocksToTrade
Recursion Pharmaceuticals Inc. Shows Early Signs of Technical Strength2025 Earnings Surprises & Fast Exit/Entry Strategy Plans - mustnews.co.kr
Recursion Pharma to reduce workforce by 20% - MSN
Recursion Pharmaceuticals Shares Dip Amid Rising R&D Costs - TipRanks
Top Executive Sells Thousands of Shares in Major Pharmaceutical Firm! - TipRanks
Recursion pharma director Khan sells $202k in shares By Investing.com - Investing.com UK
Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data (NASDAQ:RXRX) - Seeking Alpha
Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday? - MSN
Healthcare Stocks Receive Analyst Ratings: Cullinan Management, Recursion Pharmaceuticals, and Cochlear. - AInvest
RXRX Stock: Is It a Hidden Gem? - timothysykes.com
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid - MSN
Why Recursion Pharmaceuticals Stock Faces Pressure - TipRanks
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors - MSN
Recursion Pharmaceuticals: Pioneering AI-Driven Drug Discovery to Redefine Precision Medicine and Deliver Outsized Returns - AInvest
Recursion Pharmaceuticals Expands AI Drug Discovery Pipeline with New Clinical Candidates - AInvest
Will Recursion Pharmaceuticals' (RXRX) Widening Losses Challenge Its Long-Term Innovation Story? - simplywall.st
Is Recursion Pharmaceuticals' AI-Driven Drug Discovery Model Worth the High-Risk Bet? - AInvest
Largest borrow rate increases among liquid names - MSN
Indicative Borrow Rate Increases Among Liquid Names: RXRX, POET, USAR, and More - AInvest
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings - MSN
Support Zone Holds Steady for Recursion Pharmaceuticals Inc. After DipJuly 2025 Macro Moves & Trade Opportunity Analysis Reports - 선데이타임즈
Recursion Pharmaceuticals Insider Sold Shares Worth $3,263,964, According to a Recent SEC Filing - MarketScreener
Recursion Pharma CEO Gibson sells shares worth $3.26 million By Investing.com - Investing.com South Africa
Recursion Pharma CEO Gibson sells shares worth $3.26 million - Investing.com
Is Recursion On A Breakthrough Path? - timothysykes.com
Recursion Pharmaceuticals: Two Clinical Readouts In H2'25 (NASDAQ:RXRX) - Seeking Alpha
How Rising Losses and Revenue Growth at Recursion Pharmaceuticals (RXRX) Have Changed Its Investment Story - simplywall.st
From Novel Discovery to Precision Biomarkers: How Recursion is Using Data and AI to Deliver New Cancer Drugs - MarketScreener
Recursion outlines $100M partnership inflows target by end of 2026 as cash runway extends through Q4 2027 - MSN
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN
Recursion Bets Big On AI-Driven Drug Discovery, But Losses Mount - Finimize
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript - MSN
Why Recursion Pharmaceuticals Stock Tanked on Tuesday - Mitrade
Bank of America Securities Remains a Hold on Recursion Pharmaceuticals (RXRX) - The Globe and Mail
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - 富途牛牛
Recursion Pharmaceuticals Reports Q2 Loss, Beats Revenue Estimates - AInvest
Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - ca.finance.yahoo.com
Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Recursion Pharmaceuticals shares fall 1.99% premarket after reporting a wider Q2 loss. - AInvest
Recursion Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate
Recursion Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Recursion (RXRX) Q2 Revenue Jumps 33% - AOL.com
Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating - TipRanks
Recursion Pharmaceuticals and Biodexa: A High-Stakes Race in the FAP Market - AInvest
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):